Department of Gastrointestinal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Int J Colorectal Dis. 2023 Feb 9;38(1):30. doi: 10.1007/s00384-023-04326-8.
The extent of lymphadenectomy in patients with pT2 colorectal cancer (CRC) remains controversial. This study aimed to elucidate the effects of D3 and D2 lymph node dissection (LND) on survival in patients diagnosed with pT2 CRC.
This was a retrospective cohort study from a high-volume cancer center in Japan. From April 2007 to December 2020, 6273 patients with primary CRC were included in the study; among these, 616 patients diagnosed with pT2 CRC underwent radical colorectal resection. Propensity score matching (PSM) was applied to balance potential confounding factors, and a total of 104 matched pairs were extracted from the entire cohort. Independent risk factors associated with prognosis were determined by Cox regression analysis. The main outcome measures were overall survival (OS) and cancer-specific survival (CSS).
Before PSM, there was a statistically significant difference across the cohort in OS and CSS (p = 0.000 and 0.013) between D3 and D2 LND groups; the estimated hazard ratio (HR) was 2.2 (95% confidence interval (CI), 1.1-4.4, p = 0.031) for OS in the D3 LND and 4.4 (95% CI, 1.7 to 11, p = 0.0027) for CSS (p = 0.013). There was also a significant difference (p = 0.024) in OS between the D3 and D2 LND groups in the matched cohort, with an estimated HR for OS of 3.3 (95% CI, 1.2 to 9.1, p = 0.024) and an estimated HR for CSS of 7.2 (95% CI, 1.6 to 33, p = 0.011).
D3 LND had a significant survival advantage in the treatment of pT2 CRC. The results of this study provide a theoretical basis for the application of D3 LND in radical surgery for preoperative T2 CRC.
在 pT2 结直肠癌(CRC)患者中,淋巴结清扫的范围仍存在争议。本研究旨在阐明 D3 和 D2 淋巴结清扫(LND)对 pT2 CRC 患者生存的影响。
这是一项来自日本一家大容量癌症中心的回顾性队列研究。从 2007 年 4 月至 2020 年 12 月,共有 6273 例原发性 CRC 患者纳入本研究;其中,616 例 pT2 CRC 患者接受了根治性结直肠切除术。采用倾向评分匹配(PSM)来平衡潜在的混杂因素,从整个队列中提取了 104 对匹配对。通过 Cox 回归分析确定与预后相关的独立危险因素。主要观察终点为总生存期(OS)和癌症特异性生存期(CSS)。
在 PSM 之前,在 OS 和 CSS 方面,D3 和 D2 LND 组之间的队列存在统计学差异(p<0.0001 和 0.013);D3 LND 的 OS 风险比(HR)为 2.2(95%置信区间(CI),1.1-4.4,p=0.031),CSS 的 HR 为 4.4(95%CI,1.7 至 11,p=0.0027)(p=0.013)。在匹配队列中,D3 和 D2 LND 组之间的 OS 也存在显著差异(p=0.024),OS 的 HR 为 3.3(95%CI,1.2 至 9.1,p=0.024),CSS 的 HR 为 7.2(95%CI,1.6 至 33,p=0.011)。
D3 LND 在治疗 pT2 CRC 方面具有显著的生存优势。本研究结果为 D3 LND 在术前 T2 CRC 根治性手术中的应用提供了理论依据。